Company Overview and News
Eonmetall Group Bhd (Oct 5, 53.5 sen) Maintain buy with a fair value (FV) of 92 sen: We have maintained our “buy” call, forecasts and FV of 92 sen based on eight times financial year 2018 forecast earnings per share of 11.5 sen. This is at a discount to the manufacturing sector’s average one-year forward price-earnings ratio of 10 to 11 times to reflect Eonmetall’s relatively small market capitalisation.
KUALA LUMPUR (Oct 5): Shares in Eonmetall Group Bhd rose 8% in early trade today after it secured the exclusive rights from a unit of FGV Holdings Bhd to build palm fibre oil extraction plants at six selected mill locations, then own and operate them for a concession period of 10 years, before transferring their ownership to the FGV unit.
Eonmetall said its wholly owned subsidiary Eonmetall Carotene Oil Sdn Bhd (ECOSB) had entered into a build, operate, own and transfer (BOOT) arrangement with Felda’s subsidiary, Felda Palm Industries Sdn Bhd (FPISB)
7217 BSMAF 1818
KUALA LUMPUR (Oct 4): Based on corporate announcements and news flow today, companies that may be in focus on Friday (Oct 5) may include the following: Malayan Banking Bhd, Aeon Credit Service (M) Bhd, Nestle (Malaysia) Bhd, Press Metal Aluminium Holdings Bhd, Alcom Group Bhd, Eonmetall Group Bhd, FGV Holdings Bhd and DBE Gurney Resources Bhd.
1155 5139 MLYBY 7217 0900 8869 MLYNF NSLYF BSMAF 1818
KUALA LUMPUR (Oct 4): Eonmetall Group Bhd has secured the exclusive rights from a unit of FGV Holdings Bhd to build palm fibre oil extraction plants at six selected mill locations, then own and operate them for a concession period of 10 years, before transferring their ownership to the FGV unit.
7217 BSMAF 1818
KUALA LUMPUR (July 27): RHB Retail Research said Eonmetall Group Bhd may rise higher after posting a long white candle and leaving an upside gap.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...